Top Page
Mesoblast
(NASDAQ:MESO)
Mesoblast (MESO) vs. SPDR S&P 500 ETF (SPY)
Mesoblast Business Overview & Revenue Model
Mesoblast Earnings Call Summary
Mesoblast Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.20M | 17.20M | 5.90M | 7.50M | 10.21M | 7.46M |
| Gross Profit | -35.86M | 12.07M | -35.17M | -47.42M | -53.36M | -78.28M |
| EBITDA | -58.18M | -73.66M | -56.08M | -58.55M | -76.57M | -84.65M |
| Net Income | -102.14M | -102.14M | -87.96M | -81.89M | -91.35M | -98.81M |
Balance Sheet | ||||||
| Total Assets | 784.68M | 784.68M | 669.15M | 669.41M | 662.14M | 744.72M |
| Cash, Cash Equivalents and Short-Term Investments | 161.16M | 161.16M | 62.56M | 70.92M | 60.03M | 136.88M |
| Total Debt | 128.16M | 128.16M | 118.92M | 116.50M | 106.91M | 105.50M |
| Total Liabilities | 187.24M | 187.24M | 188.80M | 167.58M | 165.10M | 163.32M |
| Stockholders Equity | 597.44M | 597.44M | 480.36M | 501.84M | 497.04M | 581.40M |
Cash Flow | ||||||
| Free Cash Flow | -48.69M | -50.68M | -48.79M | -63.58M | -66.01M | -108.33M |
| Operating Cash Flow | -47.99M | -49.95M | -48.46M | -63.27M | -65.78M | -106.68M |
| Investing Cash Flow | 120.00K | 120.00K | -97.00K | -194.00K | -232.00K | -1.65M |
| Financing Cash Flow | 147.34M | 147.34M | 40.25M | 74.50M | -9.87M | 114.47M |
Mesoblast Technical Analysis
Mesoblast Risk Analysis
Mesoblast Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $2.08B | 11.47 | 25.93% | ― | 21.13% | 50.86% | |
56 Neutral | $5.75B | -16.56 | -95.40% | ― | ― | 4.32% | |
53 Neutral | $2.31B | -20.96 | -18.96% | ― | 191.53% | 5.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.39B | -7.37 | -21.37% | ― | 47.15% | -311.26% | |
49 Neutral | $2.75B | -33.04 | -37.18% | ― | 42.57% | 60.03% | |
47 Neutral | $1.67B | -56.06 | -7.52% | ― | 27.51% | 38.72% |
Mesoblast Corporate Events
On January 6, 2026, Mesoblast Limited reported to the Australian Securities Exchange that 3,000,000 unquoted “Warrants 3” (ASX code MSBAB) had lapsed after the conditions attached to these securities were not, or could no longer be, satisfied, resulting in their cessation without any consideration paid. Following this lapse, Mesoblast confirmed that its issued capital comprised approximately 1.28 billion ordinary fully paid shares and a range of remaining unquoted options and warrants, signalling a modest simplification of its capital structure but no immediate change to its ordinary share count or cash position for existing shareholders.
The most recent analyst rating on (MESO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
On December 17, 2025, Mesoblast Limited reported to the U.S. Securities and Exchange Commission that it had lodged an Appendix 3G with the Australian Securities Exchange, confirming the issue of 5 million unquoted warrants as part of a previously announced placement-linked financing. The new warrants, designated as a new class (Warrants 3) exercisable at A$2.50 per share and expiring on December 17, 2029, were issued as a commitment fee for access to a convertible note facility of up to US$50 million, which the company may draw on following shareholder approval at its 2025 AGM. Each warrant converts into one ordinary share, or in the case of American Depositary Receipts, 10 warrants convert into one ADR at an exercise price of US$16.25 per ADR, with 3 million of the warrants vesting only if Mesoblast exercises its option under the note facility. The issuance modestly increases Mesoblast’s unquoted securities and underscores its ongoing reliance on structured financing to support operations, with potential future dilution for shareholders if the warrants are exercised.
The most recent analyst rating on (MESO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
On November 25, 2025, Mesoblast Limited announced the results of its Annual General Meeting, where all proposed resolutions were passed by a poll. The resolutions included the adoption of the remuneration report, election and re-election of directors, approval of options for long-term and short-term incentives, and the approval of convertible notes and warrants. These outcomes reflect strong shareholder support and are likely to positively impact the company’s strategic direction and stakeholder confidence.
The most recent analyst rating on (MESO) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
On November 25, 2025, Mesoblast Limited announced at its Annual General Meeting that it has achieved FDA approval for Ryoncil®, a mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. This approval marks a significant milestone for Mesoblast, transitioning the company from development to commercialization with strong sales and reimbursement coverage. The success of Ryoncil® validates Mesoblast’s scientific platform and commercialization strategy, and the company is now expanding its use to additional indications and preparing for further FDA approvals for other products in its pipeline.
The most recent analyst rating on (MESO) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
On November 21, 2025, Mesoblast Limited announced a collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to initiate a pivotal trial of Ryoncil® for adults with severe acute graft versus host disease (aGvHD) who are refractory to corticosteroids. This trial aims to extend the use of Ryoncil®, already FDA-approved for children, to adults, addressing a significant unmet need due to high mortality rates in patients failing existing therapies. The trial, set to begin enrollment in early 2026, represents a substantial market opportunity, potentially 3-4 times larger than the pediatric market.
The most recent analyst rating on (MESO) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
On October 28, 2025, Mesoblast Limited announced a change in director’s interest and the issuance of new equity securities. William Burns, a director, acquired 120,000 ordinary shares through the exercise of options, increasing his total holdings. This move reflects Mesoblast’s ongoing efforts to strengthen its financial position and enhance shareholder value, potentially impacting its market standing and investor relations.
The most recent analyst rating on (MESO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
On October 20, 2025, Mesoblast Limited reported a significant increase in revenues for the quarter ended September 30, 2025, driven by the adoption of Ryoncil®, which saw a 69% increase in net sales. The assignment of a permanent J-Code by CMS on October 1, 2025, is expected to further enhance product adoption. Mesoblast has onboarded 40 transplant centers and expanded coverage to over 260 million US lives. The company plans a pivotal trial for Ryoncil® in adults with severe SR-aGvHD, aiming to extend its label to a larger population. Mesoblast’s financial position remains strong with $145 million in cash and new funding options.
The most recent analyst rating on (MESO) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.